The estimated Net Worth of N Scott Fine is at least $783 mil dollars as of 20 April 2023. Mr Fine owns over 299,402 units of Cyclo Therapeutics stock worth over $293,305 and over the last 10 years he sold CYTH stock worth over $0. In addition, he makes $489,200 as CEO & Director at Cyclo Therapeutics.
Mr has made over 7 trades of the Cyclo Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 299,402 units of CYTH stock worth $212,575 on 20 April 2023.
The largest trade he's ever made was buying 299,402 units of Cyclo Therapeutics stock on 20 April 2023 worth over $212,575. On average, Mr trades about 20,921 units every 36 days since 2015. As of 20 April 2023 he still owns at least 444,402 units of Cyclo Therapeutics stock.
You can see the complete history of Mr Fine stock trades at the bottom of the page.
N. Scott Fine is the CEO & Director at Cyclo Therapeutics.
As the CEO & Director of Cyclo Therapeutics, the total compensation of Mr Fine at Cyclo Therapeutics is $489,200. There are no executives at Cyclo Therapeutics getting paid more.
Mr Fine is 64, he's been the CEO & Director of Cyclo Therapeutics since . There are 2 older and 5 younger executives at Cyclo Therapeutics. The oldest executive at Cyclo Therapeutics, Inc. is George L. Fails, 76, who is the Exec. VP and Operations Mang..
N's mailing address filed with the SEC is C/O CYCLO THERAPEUTICS, INC., 6714 NW 16TH STREET, SUITE B, GAINESVILLE, FL, 32163.
Over the last 4 years, insiders at Cyclo Therapeutics have traded over $0 worth of Cyclo Therapeutics stock and bought 4,648,141 units worth $6,142,223 . The most active insiders traders include Holdings, Inc. Rafael, Shawn Cross, eN Scott Fine. On average, Cyclo Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $78,661. The most recent stock trade was executed by Holdings, Inc. Rafael on 1 August 2023, trading 4,000,000 units of CYTH stock currently worth $5,000,000.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Cyclo Therapeutics executives and other stock owners filed with the SEC include: